Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1046308 | 1.00 | CTSK (0.45) | CTSKGRIN1GRIN2BPPARGMAPK1 | |
| SCHEMBL11295923 | 0.90 | MAPT (0.47) | CTSKPPARGMAPK1MAPTCNR2 | |
| SCHEMBL1050227 | 0.85 | CTSK (0.43) | CTSKGRIN1GRIN2BPPARGMAPT | |
| SCHEMBL1050226 | 0.85 | CTSK (0.43) | CTSKGRIN1GRIN2BPPARGMAPT | |
| SCHEMBL1052137 | 0.84 | CTSK (0.45) | CTSKMAPTCNR2MEN1KMT2A | |
| SCHEMBL1052134 | 0.84 | CTSK (0.45) | CTSKMAPTCNR2MEN1KMT2A | |
| SCHEMBL3705615 | 0.81 | GRIN1 (0.42) | CTSKGRIN1GRIN2BPPARGMAPT | |
| SCHEMBL3705617 | 0.81 | GRIN1 (0.42) | CTSKGRIN1GRIN2BPPARGMAPT | |
| SCHEMBL1051812 | 0.81 | LMNA (0.42) | CTSKMAPTGAAKMT2AHTT | |
| SCHEMBL1051813 | 0.81 | LMNA (0.42) | CTSKMAPTGAAKMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160128993-A1 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BALTICGRUPPEN BIO AB (SE) | 2016-05-12 | — | — | US | claimed |
| EP-2451794-B1 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BALTIC BIO AB (SE) | 2016-01-27 | — | — | EP | claimed |
| US-20120183537-A1 | 1,2,4-THIAZOLOIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BETAGENON AB | 2012-07-19 | — | — | US | claimed |
| EP-2451794-A2 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BALTIC BIO AB (SE) | 2012-05-16 | — | — | EP | claimed |
| WO-2011004162-A2 | COMPOUNDS USEFUL AS MEDICAMENTS | BETAGENON AB (SE) | 2011-01-13 | — | — | WO | claimed |
| US-9675596-B2 | 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer | BALTIC BIO AB (SE) | 2017-06-13 | — | — | US | disclosed |
| US-9675596-B2 | 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer | BALTIC BIO AB (SE) | 2017-06-13 | — | — | US | disclosed |
| US-20160128993-A1 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BALTICGRUPPEN BIO AB (SE) | 2016-05-12 | — | — | US | disclosed |
| EP-2451794-B1 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BALTIC BIO AB (SE) | 2016-01-27 | — | — | EP | disclosed |
| EP-2451794-B1 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BALTIC BIO AB (SE) | 2016-01-27 | — | — | EP | disclosed |
| US-9162994-B2 | 1,2,4-thiazoloidin-3-one derivatives and their use in the treatment of cancer | BETAGENON AB (SE) | 2015-10-20 | — | — | US | disclosed |
| US-20120183537-A1 | 1,2,4-THIAZOLOIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BETAGENON AB | 2012-07-19 | — | — | US | disclosed |
| EP-2451794-A2 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BALTIC BIO AB (SE) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011004162-A2 | COMPOUNDS USEFUL AS MEDICAMENTS | BETAGENON AB (SE) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011004162-A2 | COMPOUNDS USEFUL AS MEDICAMENTS | BETAGENON AB (SE) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160128993-A1 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | HCCS, CCND3, MTNR1A | CTSK 3911/4885GRIN1 3517/4885GRIN2B 3939/4885 |
| US-20120183537-A1 | 1,2,4-THIAZOLOIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | HCCS, CCND3, MTNR1A | CTSK 3534/4885GRIN1 3686/4885GRIN2B 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.